Perrigo Company PLC (NYSE:PRGO) CFO Ronald Winowiecki sold 826 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $48.03, for a total value of $39,672.78. Following the completion of the transaction, the chief financial officer now owns 6,952 shares in the company, valued at $333,904.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
NYSE:PRGO traded down $1.43 during mid-day trading on Friday, hitting $46.34. The company’s stock had a trading volume of 763,020 shares, compared to its average volume of 1,519,862. Perrigo Company PLC has a 1 year low of $36.28 and a 1 year high of $78.90. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.92 and a quick ratio of 1.39. The stock has a market cap of $6.52 billion, a price-to-earnings ratio of 10.18, a PEG ratio of 4.85 and a beta of 1.40. The business’s fifty day moving average is $50.30 and its two-hundred day moving average is $48.47.
Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.05. The business had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.13 billion. Perrigo had a net margin of 1.87% and a return on equity of 9.57%. The company’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.22 earnings per share. Analysts anticipate that Perrigo Company PLC will post 3.95 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. SRS Capital Advisors Inc. bought a new position in Perrigo during the 2nd quarter valued at $25,000. Financial Gravity Wealth Inc. lifted its position in shares of Perrigo by 15,075.0% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 607 shares of the company’s stock worth $29,000 after buying an additional 603 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Perrigo by 833.7% in the 1st quarter. Parallel Advisors LLC now owns 803 shares of the company’s stock worth $39,000 after buying an additional 717 shares during the last quarter. Commonwealth Bank of Australia lifted its position in shares of Perrigo by 295.6% in the 2nd quarter. Commonwealth Bank of Australia now owns 890 shares of the company’s stock worth $42,000 after buying an additional 665 shares during the last quarter. Finally, CSat Investment Advisory L.P. lifted its position in shares of Perrigo by 75.2% in the 1st quarter. CSat Investment Advisory L.P. now owns 1,067 shares of the company’s stock worth $51,000 after buying an additional 458 shares during the last quarter. 88.22% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts recently weighed in on the company. Cantor Fitzgerald lowered their target price on Perrigo from $107.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 12th. SunTrust Banks lifted their target price on Perrigo to $51.00 and gave the stock a “hold” rating in a report on Monday, May 20th. ValuEngine raised Perrigo from a “strong sell” rating to a “sell” rating in a report on Thursday, August 1st. Finally, Wells Fargo & Co reissued a “hold” rating on shares of Perrigo in a research note on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $55.14.
Perrigo Company Profile
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Further Reading: Green Investing
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.